Olutasidenib demonstrates efficacy in patients with relapsed/refractory IDH1 mutant AML Presented ByDr Stéphane de Botton , Institute Gustave Roussy, France TrialPhase 2, 2102M 101 ConferenceASCO 2021 12 August, 2021 23:20